QT Interval Prolongation
Concurrent use of clofazimine, quinolones, or other QT-prolonging agents compounds the risk of torsades de pointes or sudden cardiac death. Bedaquiline and delamanid metabolites inhibit the hERG potassium channel, delaying repolarisation a…
1 sources - 5 claims
Concurrent use of clofazimine, quinolones, or other QT-prolonging agents compounds the risk of torsades de pointes or sudden cardiac death. Bedaquiline and delamanid metabolites inhibit the hERG potassium channel, delaying repolarisation and prolonging QT interval. QTcB or QTcF above 500 ms or an increase greater than 60 ms from baseline is the established threshold for potentially fatal torsades de pointes risk. Hypokalaemia increases QT prolongation risk in MDR-TB patients receiving bedaquiline. Patients older than 45 showed longer QT intervals than younger patients after 1 and 6 months of therapy.